Medicortex International AB (publ) (NGM:MEDFIN)
Sweden · Delayed Price · Currency is SEK 1.140
0.00 (0.00%)
At close: Aug 26, 2026
NGM:MEDFIN Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue | 4.73 | 4.92 | 7.15 | 18.78 | 15.77 | 17.1 |
Revenue Growth | -24.73% | -31.21% | -61.94% | 19.07% | -7.76% | 57.09% |
Cost of Revenue | 2.58 | 2.46 | 3.18 | 8.8 | 6.95 | 6.82 |
Gross Profit | 2.15 | 2.45 | 3.97 | 9.97 | 8.83 | 10.28 |
Selling, General & Admin | 7.46 | 7.62 | 8.99 | 17.02 | 16.85 | 13.35 |
Other Operating Expenses | 0.06 | -0.01 | 0.12 | -0.61 | -3.39 | -0.23 |
Operating Expenses | 8.05 | 8.32 | 10.89 | 18.03 | 14.43 | 14 |
Operating Income | -5.9 | -5.87 | -6.92 | -8.06 | -5.6 | -3.73 |
Interest Expense | -0.41 | -0.58 | -1.08 | -1.37 | -0.21 | -0.14 |
Interest & Investment Income | 0.01 | 0.01 | 0.03 | 0.01 | 0 | 0 |
Earnings From Equity Investments | 0.23 | -3.12 | -26.1 | -14.72 | 2.62 | 0.57 |
Other Non Operating Income (Expenses) | -0 | - | -0 | -0 | - | -0 |
Pretax Income | -6.07 | -9.56 | -34.07 | -24.14 | -3.19 | -3.29 |
Income Tax Expense | - | - | 0 | 0.31 | - | 0.3 |
Earnings From Continuing Operations | -6.07 | -9.56 | -34.08 | -24.45 | -3.19 | -3.6 |
Minority Interest in Earnings | - | - | 0.94 | 2.01 | 2.13 | 0.38 |
Net Income | -6.07 | -9.56 | -33.14 | -22.44 | -1.06 | -3.21 |
Net Income to Common | -6.07 | -9.56 | -33.14 | -22.44 | -1.06 | -3.21 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 3 | 2 | 2 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 3 | 2 | 2 | 0 | 0 | 0 |
Shares Change | 24.87% | 11.05% | 1671.67% | 37.66% | 38.12% | 29.31% |
EPS (Basic) | -2.20 | -3.90 | -15.03 | -180.33 | -11.72 | -49.08 |
EPS (Diluted) | -2.20 | -3.90 | -15.03 | -180.33 | -11.72 | -49.08 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -3.29 | -3.98 | -8.66 | -11.59 | -4.79 | 0.11 |
Free Cash Flow Per Share | -1.19 | -1.63 | -3.93 | -93.11 | -53.02 | 1.64 |
Gross Margin | 45.47% | 49.87% | 55.54% | 53.12% | 55.96% | 60.09% |
Operating Margin | -124.84% | -119.29% | -96.79% | -42.90% | -35.53% | -21.79% |
Profit Margin | -128.38% | -194.40% | -463.61% | -119.51% | -6.72% | -18.79% |
Free Cash Flow Margin | -69.51% | -80.96% | -121.14% | -61.71% | -30.39% | 0.63% |
EBITDA | -5.37 | -5.44 | -5.4 | -7.07 | -5.16 | -3.31 |
EBITDA Margin | -113.54% | -110.65% | -75.59% | -37.65% | -32.73% | -19.36% |
D&A For EBITDA | 0.53 | 0.42 | 1.52 | 0.99 | 0.44 | 0.42 |
EBIT | -5.9 | -5.87 | -6.92 | -8.06 | -5.6 | -3.73 |
EBIT Margin | -124.84% | -119.29% | -96.79% | -42.90% | -35.53% | -21.79% |
Revenue as Reported | 4.67 | 4.93 | 7.03 | 19.66 | 19.21 | 17.35 |